Categories AlphaGraphs, Earnings, LATEST, Leisure & Entertainment
Gamestop (GME) Q2 revenue up 25%, loss narrows
Video game retailer GameStop Corp. (NYSE: GME) on Tuesday reported a narrower net loss for the second quarter of 2021, aided by a 25% increase in sales. The company’s stock, which has stabilized after the recent roller-coaster ride, dropped soon after the announcement.
Adjusted net loss improved to $0.76 per share in the July quarter from $1.42 per share in the comparable period of 2020. The latest number missed the estimates.
On an unadjusted basis, it was a net loss of $61.6 million or $0.85 per share, compared to a loss of $111.3 million or $1.71 per share in the second quarter of last year. The improvement reflects a 25% increase in net sales to $1.18 billion. Analysts had forecast a slower top-line growth.
Read management/analysts’ comments on GameStop’s Q2 earnings
Shares of Gamestop closed Tuesday’s trading lower and lost further in the after-hours. The stock has gained 24% in the past 30 days alone.
Prior Performance
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
Infographic: Highlights of DocuSign’s (DOCU) Q1 2024 results
DocuSign, Inc. (NASDAQ: DOCU), a leading provider of electronic signature solutions, Thursday reported first-quarter earnings. It also provided guidance for the second quarter and fiscal 2024. The company's top line
Macy’s (M): A few points to consider if you have an eye on this retailer
Shares of Macy’s, Inc. (NYSE: M) stayed in red on Thursday. The stock has dropped 22% year-to-date and 32% over the past 12 months. The retailer witnessed sales and profit
Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific co-founder Dr. Jonathan Kurtis received a new patent
